BioSpace News Archive

Aquestive Therapeutics, Inc. announced today that the management team will participate in three upcoming investor conferences in September as follows: H.C. Wainwright 23rd Annual Global Investment Conference: on demand corporate presentation available from September 13 - 15

Akero Therapeutics, Inc. today announced that members of the management team will present at the Morgan Stanley Virtual Global Healthcare Conference on Wednesday, September 15, 2021 at 11:45 a.m. (ET).

BeyondSpring Inc. today announced that management will host a conference call to report its financial results for the second quarter ended June 30, 2021 and provide an update on recent corporate events on Friday, September 10, 2021 at 8:00 AM Eastern Time.

Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that it has completed patient enrollment for its pivotal phase 3 study of CAN-2409 immunotherapy in patients with intermediate-high risk localized prostate cancer.

Motus GI Holdings, Inc. announced today that its management team is scheduled to participate at the two upcoming virtual investor conferences in September 2021.

Protara Therapeutics, Inc. today announced that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021.

Cocrystal Pharma, Inc announces that management will present at the 23rd Annual Global Investment Conference being held September 13-15, 2021. webcast of the presentation will be available on the IR Calendar of the Cocrystal Pharma website beginning at 1:00 a.m. Eastern time on Monday, September 13, 2021. “We look forward to discussing progress an

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug Administration (FDA)

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new clinical data from the NAVABLATE study, which highlights the much anticipated safety and performance results on microwave ablation used bronchoscopically with the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology in conjunction with the Medtronic electromagnetic navigation bronchoscopy system.

Alcresta Therapeutics, Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has published a Local Coverage Determination (LCD) on enteral nutrition (LCD ID No. 38955) that confirms coverage for RELiZORB® (immobilized lipase).